Intracardiac hemodynamic parameters in male patients with essential hypertension carrying polymorphic variants of the cardiotrophin-1 gene
Article Sidebar
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Main Article Content
https://orcid.org/0000-0002-6542-9313
Abstract
The aim – improvement of diagnosing the intracardiac and systemic hemodynamic changes in male left ventricular hypertrophy (LVH) patients with underlying essential hypertension (EH) being carriers of polymorphic variants of the corresponding coding gene (rs8046707) using the cardiotrophin-1 (CT-1) biomarker.
Materials and methods. The study involved 70 male individuals without signs of cardiovascular pathology and LVH of other etiology, aged 48.81±0.78 years, and 50 male LVH patients with underlying EH without signs of chronic heart failure, aged 50.62±0.73 years. All study participants underwent a standard echocardiographic examination, blood serum CT-1 concentration enzyme-linked immunosorbent assay (ELISA), and CT-1 gene polymorphism (rs8046707) test of venous blood samples by polymerase chain reaction.
Results. The CT-1 blood serum concentration in GG-genotype individuals without signs of cardiovascular pathology (n=31) was found to be lower than that in carriers of GA + AA genotypes (n=39), being equaled to 55.77±2.53 pg/ml and 92.46±1.54 pg/ml, respectively (p<0.001). The CT-1 blood plasma concentration in LVH subjects was significantly higher than in the control group patients, equaling 188.22±7.95 pg/ml and 282.33±11.52 pg/ml in GG males (n=22) and in GA + AA genotype carriers (n=28), respectively (p<0.001). The Spearman rank correlation method was used to establish a correlation between blood plasma CT-1 concentration and echocardiography readings.
Conclusions. Stage II EH patients being carriers of CT-1 gene GA + AA genotypes demonstrated higher blood plasma CT-1 concentrations and correlation with echocardiography indicators. This fact suggests that changes in wall thickness and myocardial mass of EH II patients can be diagnosed using the above-mentioned marker as an additional ascertaining indicator.
Article Details
Keywords:
References
Abdul-Ghani M, Suen C, Jiang B, et al. Cardiotrophin 1 stimulates beneficial myogenic and vascular remodeling of the heart. Cell Res. 2017 Oct;27(10):1195-1215. https://doi.org/10.1038/cr.2017.87
Bornstein AB, Rao SS, Marwaha K. Left Ventricular Hypertrophy. 2023 Aug 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan. PMID: 32491466. https://pubmed.ncbi.nlm.nih.gov/32491466/
Jekell A, Nilsson PM, Kahan T. Treatment of Hypertensive Left Ventricular Hypertrophy. Curr Pharm Des. 2018;24(37):4391-6. https://doi.org/10.2174/1381612825666181203092918
Li H, Sureda A, Devkota HP, Pittalà V, Barreca D, Silva AS, et al. Curcumin, the golden spice in treating cardiovascular diseases. Biotechnol Adv. 2020 Jan-Feb;38:107343. https://doi.org/10.1016/j.biotechadv.2019.01.010
Bozkurt B, Ahmad T, Alexander KM, Baker WL, Bosak K, Breathett K, et al. Heart Failure Epidemiology and Outcomes Statistics: A Report of the Heart Failure Society of America. J Card Fail. 2023;29(10):1412-51. https://doi.org/10.1016/j.cardfail.2023.07.006
Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020;16(4):223-37. https://doi.org/10.1038/s41581-019-0244-2
Watanabe T, Konii H, Sato K. Emerging Roles of Cardiotrophin-1 in the Pathogenesis and Biomarker of Atherosclerosis. J. 2018;1(1):94-105. https://doi.org/10.3390/j1010010
Matokhniuk MO, Limanskiy OV, Maiko OV, Zhebel V, Shevchuk OK, Palii IK. Prognostic significance of blood marker of hypertrophy – cardiotrophin-1 when carrying different variants of its gene in men with essential hypertension. Wiad Lek. 2021;74(2):273-7. https://doi.org/10.36740/WLek202102126
Lutz SZ, Franck O, Böhm A, Machann J, Schick F, Machicao F, et al. Common genetic variation in the human CTF1 locus, encoding cardiotrophin-1, determines insulin sensitivity. PLoS One. 2014 Jul 15;9(7):e100391. https://doi.org/10.1371/journal.pone.0100391
Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018. https://doi.org/10.1093/eurheartj/ehy339
Monserrat L, López B, González A, Hermida M, Fernández X, Ortiz M, et al. Cardiotrophin-1 plasma levels are associated with the severity of hypertrophy in hypertrophic cardiomyopathy. Eur Heart J. 2011 Jan;32(2):177-83. https://doi.org/10.1093/eurheartj/ehq400
Song K, Wang S, Huang B, Luciano A, Srivastava R, Mani A. Plasma cardiotrophin-1 levels are associated with hypertensive heart disease: a meta-analysis. J Clin Hypertens (Greenwich). 2014 Sep;16(9):686-92. https://doi.org/10.1111/jch.12376
Matokhnyuk MO, Palagniuk HO, Franchuk SV, Zhebel VM. Cardiotrophin-1 as a possible marker of myocardial remodeling in patients with essential hypertension, carrying polymorphic variants of the coding gene. UJC [Internet]. 2022 Sep 19 [cited 2024 May 27];29(3-4):30-5. https://doi.org/10.31928/2664-4479-2022.3-4.3035
Martínez-Martínez E, Brugnolaro C, Ibarrola J, Ravassa S, Buonafine M, López B, et al. CT-1 (Cardiotrophin-1)-Gal-3 (Galectin-3) Axis in Cardiac Fibrosis and Inflammation. Hypertension. 2019 Mar;73(3):602-11. https://doi.org/10.1161/HYPERTENSIONAHA.118.11874
Vlahodimitris I, Karangelis D, Moschaki M, Moyssakis I, Christodoulou KC, Perrea DN, et al. Cardiotrophin-1 in Asymptomatic Hypertensive Patients With Mild Diastolic Dysfunction: Potential Prognostic Value in Early Stages of Hypertensive Heart Disease. Cureus. 2023 Oct 5;15(10):e46516. https://doi.org/10.7759/cureus.46516
Sharif S, Saleem A, Naz S, Rashid F, Iqtedar M, Kaleem A, et al. Increased Expression of Cardiotrophin-1 in Cardiomyopathy Patients. Balkan J Med Genet. 2021 Jul 27;24(1):21-6. https://doi.org/10.2478/bjmg-2021-0008